The antibody detects endogenous levels of total LIN28B protein.
Purification
Affinity purified
Immunogen
Peptide sequence around AA 242-246 ( P-S-V-Q-K) derived from Human LIN28B Antibodies were produced by immunizing rabbits with synthetic peptide and KLH conjugates.
LIN28B
Reactivity: Human
IP, IHC (fp)
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Western blotting: 1:500-1:1000
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
Phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C/-20 °C
Storage Comment
Store at -20 °C for long term preservation (recommended). Store at 4 °C for short term use.
Target
LIN28B
(Lin-28 Homolog B (LIN28B))
Alternative Name
LIN28B
Background
Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. Mediates MYC-mediated let-7 repression. Isoform 1, when overexpressed, stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth.